Literature DB >> 24120539

Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.

Praveen Kumar Suryadevara1, Kishore Kumar Racherla, Srinivas Olepu, Neil R Norcross, Hari Babu Tatipaka, Jennifer A Arif, Joseph D Planer, Galina I Lepesheva, Christophe L M J Verlinde, Frederick S Buckner, Michael H Gelb.   

Abstract

New dialkylimidazole based sterol 14α-demethylase inhibitors were prepared and tested as potential anti-Trypanosoma cruzi agents. Previous studies had identified compound 2 as the most potent and selective inhibitor against parasite cultures. In addition, animal studies had demonstrated that compound 2 is highly efficacious in the acute model of the disease. However, compound 2 has a high molecular weight and high hydrophobicity, issues addressed here. Systematic modifications were carried out at four positions on the scaffold and several inhibitors were identified which are highly potent (EC50 <1 nM) against T. cruzi in culture. The halogenated derivatives 36j, 36k, and 36p, display excellent activity against T. cruzi amastigotes, with reduced molecular weight and lipophilicity, and exhibit suitable physicochemical properties for an oral drug candidate.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CYP51; Chagas disease; Dialkylimidazole; Sterol 14-alpha demethylase; Trypanosoma cruzi

Mesh:

Substances:

Year:  2013        PMID: 24120539      PMCID: PMC4111244          DOI: 10.1016/j.bmcl.2013.08.015

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

Review 1.  A critical review on Chagas disease chemotherapy.

Authors:  José Rodriques Coura; Solange L de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-01       Impact factor: 2.743

Review 2.  Specific chemotherapy of Chagas disease: controversies and advances.

Authors:  Julio A Urbina; Roberto Docampo
Journal:  Trends Parasitol       Date:  2003-11

3.  CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase.

Authors:  Galina I Lepesheva; Natalia G Zaitseva; W David Nes; Wenxu Zhou; Miharu Arase; Jialin Liu; George C Hill; Michael R Waterman
Journal:  J Biol Chem       Date:  2005-11-30       Impact factor: 5.157

4.  Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.

Authors:  Praveen Kumar Suryadevara; Srinivas Olepu; Jeffrey W Lockman; Junko Ohkanda; Mandana Karimi; Christophe L M J Verlinde; James M Kraus; Jan Schoepe; Wesley C Van Voorhis; Andrew D Hamilton; Frederick S Buckner; Michael H Gelb
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

5.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

6.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

7.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.

Authors:  Oliver Hucke; Michael H Gelb; Christophe L M J Verlinde; Frederick S Buckner
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

8.  A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.

Authors:  Frederick Buckner; Kohei Yokoyama; Jeffrey Lockman; Kendra Aikenhead; Junko Ohkanda; Martin Sadilek; Said Sebti; Wesley Van Voorhis; Andrew Hamilton; Michael H Gelb
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

9.  An estimate of the burden of Chagas disease in the United States.

Authors:  Caryn Bern; Susan P Montgomery
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

10.  Global economic burden of Chagas disease: a computational simulation model.

Authors:  Bruce Y Lee; Kristina M Bacon; Maria Elena Bottazzi; Peter J Hotez
Journal:  Lancet Infect Dis       Date:  2013-02-08       Impact factor: 25.071

View more
  5 in total

1.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.

Authors:  Shilpi Khare; Xianzhong Liu; Monique Stinson; Ianne Rivera; Todd Groessl; Tove Tuntland; Vince Yeh; Ben Wen; Valentina Molteni; Richard Glynne; Frantisek Supek
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

2.  Synthesis and biological evaluation of N-alkyl naphthoimidazoles derived from β-lapachone against Trypanosoma cruzi bloodstream trypomastigotes.

Authors:  Ari Miranda da Silva; Leonardo Araújo-Silva; Ana Cristina S Bombaça; Rubem F S Menna-Barreto; Claudio Eduardo Rodrigues-Santos; Aurélio B Buarque Ferreira; Solange L de Castro
Journal:  Medchemcomm       Date:  2017-02-27       Impact factor: 3.597

3.  Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.

Authors:  Pedro Igor Camara de Oliveira; Paulo Henrique de Santana Miranda; Estela Mariana Guimaraes Lourenço; Priscilla Suene de Santana Nogueira Silverio; Euzebio Guimaraes Barbosa
Journal:  Mol Divers       Date:  2020-06-16       Impact factor: 2.943

Review 4.  Drug strategies targeting CYP51 in neglected tropical diseases.

Authors:  Jun Yong Choi; Larissa M Podust; William R Roush
Journal:  Chem Rev       Date:  2014-10-22       Impact factor: 60.622

5.  Sterol biosynthesis is required for heat resistance but not extracellular survival in leishmania.

Authors:  Wei Xu; Fong-Fu Hsu; Eda Baykal; Juyang Huang; Kai Zhang
Journal:  PLoS Pathog       Date:  2014-10-23       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.